Zenas BioPharma to Present at the Jefferies Global Healthcare Conference
Zenas BioPharma (Nasdaq: ZBIO), a clinical-stage biopharmaceutical company focused on autoimmune disease therapies, has announced its upcoming participation in the Jefferies Global Healthcare Conference. The company's management will deliver a presentation on Thursday, June 5, 2025, at 1:25 p.m. ET. Interested parties can access both the live webcast and archived replay of the presentation through the "Events and Presentations" section of Zenas BioPharma's website under Investor & Media Relations.
Zenas BioPharma (Nasdaq: ZBIO), un'azienda biofarmaceutica in fase clinica specializzata in terapie per malattie autoimmuni, ha annunciato la sua prossima partecipazione alla Jefferies Global Healthcare Conference. Il management dell'azienda terr脿 una presentazione gioved矛 5 giugno 2025 alle 13:25 ET. Gli interessati potranno seguire sia la diretta streaming sia la registrazione della presentazione nella sezione "Eventi e Presentazioni" del sito web di Zenas BioPharma, nella sezione Investor & Media Relations.
Zenas BioPharma (Nasdaq: ZBIO), una compa帽铆a biofarmac茅utica en etapa cl铆nica centrada en terapias para enfermedades autoinmunes, ha anunciado su pr贸xima participaci贸n en la Jefferies Global Healthcare Conference. La direcci贸n de la empresa realizar谩 una presentaci贸n el jueves 5 de junio de 2025 a la 1:25 p.m. ET. Las personas interesadas podr谩n acceder tanto a la transmisi贸n en vivo como a la repetici贸n archivada de la presentaci贸n a trav茅s de la secci贸n "Eventos y Presentaciones" en el sitio web de Zenas BioPharma, bajo Relaciones con Inversores y Medios.
Zenas BioPharma (雮橃姢雼�: ZBIO)電� 鞛愱皜氅挫棴 歆堩櫂 旃橂鞝滌棎 欷戩爯鞚� 霊� 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎� 須岇偓搿�, Jefferies Global Healthcare Conference鞐� 瓿� 彀戈皜頃� 鞓堨爼鞛勳潉 氚滍憸頄堨姷雼堧嫟. 須岇偓 瓴届榿歆勳潃 2025雲� 6鞗� 5鞚� 氇╈殧鞚� 鞓ろ泟 1鞁� 25攵�(霃欕秬 鞁滉皠)鞐� 氚滍憸毳� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 甏�鞁� 鞛堧姅 攵勲摛鞚� Zenas BioPharma 鞗轨偓鞚错姼鞚� 韴瀽鞛� 氚� 氙鸽敂鞏� 甏�瓿� 靹轨厴 雮� "鞚措菠韸� 氚� 氚滍憸"鞐愳劀 靸濎瓿� 氚� 雲鬼檾霅� 氚滍憸毳� 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟.
Zenas BioPharma (Nasdaq : ZBIO), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans les th茅rapies des maladies auto-immunes, a annonc茅 sa prochaine participation 脿 la Jefferies Global Healthcare Conference. La direction de l'entreprise pr茅sentera le jeudi 5 juin 2025 脿 13h25 ET. Les int茅ress茅s pourront acc茅der 脿 la fois au webcast en direct et 脿 la rediffusion de la pr茅sentation via la section "脡v茅nements et Pr茅sentations" du site web de Zenas BioPharma, dans la rubrique Relations avec les investisseurs et les m茅dias.
Zenas BioPharma (Nasdaq: ZBIO), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase mit Fokus auf Therapien f眉r Autoimmunerkrankungen, hat seine bevorstehende Teilnahme an der Jefferies Global Healthcare Conference angek眉ndigt. Das Management des Unternehmens wird am Donnerstag, den 5. Juni 2025, um 13:25 Uhr ET eine Pr盲sentation halten. Interessierte k枚nnen sowohl das Live-Webcast als auch die archivierte Wiedergabe der Pr盲sentation 眉ber den Bereich "Events and Presentations" auf der Website von Zenas BioPharma unter Investor & Media Relations abrufen.
- None.
- None.
WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (鈥淶enas鈥� or the 鈥淐ompany鈥�) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced management鈥檚 presentation at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 1:25 p.m. ET.
A live webcast and archived replay of the Company鈥檚 presentation can be accessed under 鈥淓vents and Presentations鈥� in the section of the Zenas BioPharma .
About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas鈥� lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and Fc纬RIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab鈥檚 unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. For more information about Zenas BioPharma, please visit聽聽and follow us on聽.
The Zenas BioPharma word mark, logo mark, and the 鈥渓ightning bolt鈥� design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.
Investor and Media Contact:
Argot Partners
FAQ
When is Zenas BioPharma (ZBIO) presenting at the Jefferies Global Healthcare Conference 2025?
How can I watch Zenas BioPharma's (ZBIO) presentation at the Jefferies Healthcare Conference?
What is Zenas BioPharma's (ZBIO) main business focus?
What stock exchange is Zenas BioPharma (ZBIO) listed on?
